Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone

被引：0
|
作者：
Bureau, M. [1 ]
Chatelier, T. [2 ]
Perennec, T. [1 ]
Goronflot, T. [3 ]
Greilsamer, C. [4 ]
Chene, A-L. [5 ]
Affi, R. [1 ]
Bennouna, J. [1 ]
Pons-Tostivint, E. [1 ]
机构：
[1] Univ Hosp Nantes, Dept Pneumol, Thorac Med Oncol Funct Unit, Nantes, France
[2] Clin Mutualiste Estuaire, Med Oncol, St Nazaire, France
[3] Univ Hosp Nantes, Biostat Dept, Nantes, France
[4] Hosp La Roche Sur Yon, Med Oncol, La Roche Sur Yon, France
[5] Univ Hosp Nantes, Pneumol Dept, Nantes, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1295P
引用
收藏
页码：S1004 / S1004
页数：1
相关论文
共 50 条
  • [21] PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC)
    Nesline, Mary K.
    Pabla, Sarabjot
    Lee, Yong Hee
    DePietro, Paul
    Early, Amy
    Klein, Roger
    Zhang, Shengle
    Conroy, Jeffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Early Changes in Tumor Size in Patients Treated for Advanced Stage Nonsmall Cell Lung Cancer Do Not Correlate With Survival Reply
    Birchard, Katherine R.
    Patz, Edward E., Jr.
    CANCER, 2010, 116 (06) : 1616 - 1616
  • [23] Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
    Ali, Wael Abdullah Sultan
    Hui, Pan
    Ma, Yuxiang
    Wu, Yuehan
    Zhang, Yang
    Chen, Yukun
    Hong, Shaodong
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (22)
  • [24] Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
    Boeri, Mattia
    Milione, Massimo
    Proto, Claudia
    Signorelli, Diego
    Lo Russo, Giuseppe
    Galeone, Carlotta
    Verri, Carla
    Mensah, Mavis
    Centonze, Giovanni
    Martinetti, Antonia
    Sottotetti, Elisa
    Pastorino, Ugo
    Garassino, Marina Chiara
    Sozzi, Gabriella
    CLINICAL CANCER RESEARCH, 2019, 25 (07) : 2166 - 2173
  • [25] Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy
    He, Li-Na
    Fu, Sha
    Zhang, Xuanye
    Hu, Qiaozhen
    Du, Wei
    Li, Haifeng
    Chen, Tao
    Chen, Chen
    Jiang, Yongluo
    Zhou, Yixin
    Lin, Zuan
    Yang, Yunpeng
    Huang, Yan
    Zhao, Hongyun
    Fang, Wenfeng
    Zhang, Li
    Hong, Shaodong
    LUNG CANCER, 2021, 158 : 1 - 8
  • [26] Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Gon, Yasuhiro
    Takahashi, Toshiaki
    LUNG CANCER, 2021, 151 : 60 - 68
  • [27] Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
    Lin, Shu-Yung
    Yang, Ching-Yao
    Liao, Bin-Chi
    Ho, Chao-Chi
    Liao, Wei-Yu
    Chen, Kuan-Yu
    Tsai, Tzu-Hsiu
    Hsu, Chia-Lin
    Hsu, Wei-Hsun
    Su, Kang-Yi
    Chang, Yih-Leong
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Shih, Jin-Yuan
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    JOURNAL OF CANCER, 2018, 9 (10): : 1813 - 1820
  • [28] Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
    Friedlaender, Alex
    Metro, Giulio
    Signorelli, Diego
    Gili, Alessio
    Economopoulou, Panagiota
    Roila, Fausto
    Banna, Giuseppe
    De Toma, Alessandro
    Camerini, Andrea
    Christopoulou, Athina
    Lo Russo, Giuseppe
    Banini, Marco
    Galetta, Domenico
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Mountzios, Giannis
    Garassino, Marina C.
    Addeo, Alfredo
    ACTA ONCOLOGICA, 2020, 59 (09) : 1058 - 1063
  • [29] The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
    Carlos Zamora Atenza
    Geòrgia Anguera
    Mariona Riudavets Melià
    Letícia Alserawan De Lamo
    Ivana Sullivan
    Andrés Barba Joaquin
    Jorgina Serra Lopez
    M. Angels Ortiz
    Maria Mulet
    Sílvia Vidal
    Margarita Majem
    Cancer Immunology, Immunotherapy, 2022, 71 : 1823 - 1835
  • [30] The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
    Zamora Atenza, Carlos
    Anguera, Georgia
    Riudavets Melia, Mariona
    Alserawan De Lamo, Leticia
    Sullivan, Ivana
    Barba Joaquin, Andres
    Serra Lopez, Jorgina
    Angels Ortiz, M.
    Mulet, Maria
    Vidal, Silvia
    Majem, Margarita
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1823 - 1835
12345